PACTR201502001037220Other未知
[rVSV¿G-ZEBOV] Ebola Prevention Vaccine Evaluation in Sierra Leone
.S. Centers for Disease Control and Prevention0 个研究点目标入组 6,000 人开始时间: 2015年2月16日最近更新:
试验速览
- 阶段
- 未知
- 状态
- Other
- 发起方
- 入组人数
- 6,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Year(s) 至 100 Year(s)(—)
- 性别
- All
入选标准
- •1.Age 18 years or older.
- •2.Member of target population at time of enrollment:
- •-Active worker in an Ebola care, holding, or treatment center (may include physicians, nurses, nurse aides, lab technicians, pharmacists, pharmacy technicians, cleaners, and security and administrative staff);
- •-Active worker in a facility providing non-Ebola-related healthcare (may include physicians, nurses, nurse aides, lab technicians, pharmacists, pharmacy technicians, cleaners, and security and administrative staff);
- •-Active frontline worker in one of the following job categories: surveillance team, ambulance team, burial worker or worker responsible for swabbing deceased persons)
- •3.Reasonably anticipates living in Sierra Leone for the 18-24 weeks following enrollment.
- •4.Reachable by phone throughout the 6 month post-vaccination safety follow-up period.
- •5.Willing to adhere to personal protective equipment (PPE) and infection control recommendations.
- •6.Able and willing to complete the informed consent process and study procedures.
- •7.Willing to receive vaccine in either the immediate or the deferred trial arms, according to random assignment.
排除标准
- •1.History of Ebola (self-report).
- •2.Prior receipt of experimental Ebola or Marburg vaccine.
- •3.History of human immunodeficiency virus (HIV) or clinically important immunodeficiency (self-report).
- •4.Any history of allergy or anaphylaxis to prior vaccines.
- •5.Breast-feeding an infant or child.
- •6.Any reason the investigator suspects that data collected from this person would be incomplete or of poor quality.
- •7.Current pregnancy (a negative urine pregnancy test is required for women participants younger than 50 years of age who self report as not pregnant).
- •8.Currently being followed for known exposure to Ebola.
- •9.Known experimental research agents or other vaccine within 28 days (4 weeks) before vaccination.
- •10.Fever greater than or equal to 38.0°C (greater than or equal to 100.4°F) at time of vaccination.
研究者
相似试验
已完成
不适用
Ebola Vaccine Ring Vaccination Trial in GuineaEbola Virus DiseasePACTR201503001057193World Health Organization21,500
进行中(未招募)
1 期
Partnership for Research on Ebola VACcinationsEbola virus disease (EVD)MedDRA version: 21.1Level: LLTClassification code 10014074Term: Ebola virus infectionSystem Organ Class: 100000004862EUCTR2017-001798-18-Outside-EU/EEAInserm
尚未招募
不适用
Partnership for Research on Ebola VACcination (PREVAC)EbolaPACTR201712002760250ational Institute of Allergy and Infectious Diseases (NIAID)2,800
已完成
1 期
Vaccine Treatment for Ebola Virus in Healthy Adults (V920-001)Ebola VirusNCT02269423Merck Sharp & Dohme LLC39
进行中(未招募)
1 期
Pneumococcal vaccine against atherosclerosisHealthy male volunteersMedDRA version: 19.0Level: LLTClassification code 10003601Term: AtherosclerosisSystem Organ Class: 100000004866EUCTR2015-005650-35-NLCentre for Human Drug Research24
